Comment on: Rowan et al. Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU): Body Composition at 2 Years of Age. Diabetes Care 2011;34:2279–2284
Abstract
We applaud Dr. Rowan and the MiG TOFU (Metformin in Gestational diabetes: The Offspring Follow-Up) investigators for their intense efforts at following the 2-year offspring outcomes from the MiG trial (1). Understanding how in utero exposures impact longer-term offspring consequences is critical. However, we feel compelled to caution against overinterpretation of this study's findings.
Of note, 46% of the mothers in the metformin group required insulin to achieve adequate glycemic control (1); therefore, ∼50% in this group actually received both. Although 43% of the total infant cohort received anthropometric measures at 2 years, only ∼15% received dual-energy X-ray absorptiometry (DEXA) scans, thus potentially biasing the results. The absence of any differences in the …
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.